Literature DB >> 1907589

Anticardiolipin antibodies in patients with venous thrombosis.

S Kapiotis1, W Speiser, I Pabinger-Fasching, P A Kyrle, K Lechner.   

Abstract

The levels of anticardiolipin antibodies (ACA) and lupus anticoagulant (LAC) were measured in 266 consecutive unselected patients with a history of venous thrombosis. 19 (7.1%) had elevated levels of IgG- or IgM-ACA. The prevalence of LAC was 1 of 266 (0.4%) in the whole patient group and 1 of 19 (5.3%) in the ACA-positive group. Patients with elevated ACA levels did not differ from those with normal ACA with regard to age at the first thrombosis, risk of recurrence, presence of arterial thrombosis, and other clinical features. 8 out of 19 (42.1%) patients with elevated ACA levels also had elevated levels of antinuclear antibodies, but only 1 fulfilled the criteria of systemic lupus erythematosus. These data indicate that in some patients with elevated ACA, autoimmune processes may be present. The clinical significance of elevated ACA levels is uncertain.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1907589     DOI: 10.1159/000216197

Source DB:  PubMed          Journal:  Haemostasis        ISSN: 0301-0147


  5 in total

1.  Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.

Authors:  T Jonsdottir; J Forslid; A van Vollenhoven; A Harju; S Brannemark; L Klareskog; R F van Vollenhoven
Journal:  Ann Rheum Dis       Date:  2004-04-05       Impact factor: 19.103

Review 2.  Anticardiolipin antibodies and cardiovascular disease.

Authors:  K W Muir
Journal:  J R Soc Med       Date:  1995-08       Impact factor: 5.344

3.  Etanercept and venous thromboembolism: a case series.

Authors:  Ashima Makol; Madhusudan Grover; Carla Guggenheim; Houria Hassouna
Journal:  J Med Case Rep       Date:  2010-01-15

4.  Transient lupus anticoagulant associated with hypoprothrombinemia and factor XII deficiency following adenovirus infection.

Authors:  U Jaeger; S Kapiotis; I Pabinger; E Puchhammer; P A Kyrle; K Lechner
Journal:  Ann Hematol       Date:  1993-08       Impact factor: 3.673

5.  Antiphospholipid antibodies during 6-month treatment with infliximab: a preliminary report.

Authors:  Bogdan Kolarz; Maria Majdan; Dorota A Darmochwal-Kolarz; Magdalena Dryglewska
Journal:  Med Sci Monit       Date:  2014-07-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.